Advertisement

Topics

Vernalis hit by fresh U.S. setback for cough and cold drug

04:18 EDT 7 Aug 2017 | Reuters

LONDON (Reuters) - Shares in Vernalis fell 5.3 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States.

Original Article: Vernalis hit by fresh U.S. setback for cough and cold drug

NEXT ARTICLE

More From BioPortfolio on "Vernalis hit by fresh U.S. setback for cough and cold drug"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...